Pressmeddelanden

Almost 1,000 Swedish patients received cancer treatment in Finland in 2020–2023

In 2020–2023, almost 1,000 Swedish patients were treated at Docrates Cancer Center in Finland. Of these patients, 40% came from the Stockholm region, about 15% from Västra Götaland, about 15% from Skåne and the remaining 30% from all over Sweden. Patients of all ages have come to Docrates for treatment, but about half of the patients were aged 56–70 years old. The majority of the patients who...

Research Professionals of the Year honoured for the ninth time – Tuomo Alanko is Researcher of the Year

Organised for the ninth time, the vote received more than 60 proposals, on the basis of which the panel of experts selected the Researcher, Research Nurse and Clinical Research Associate (CRA) of the Year.  The Clinical Trials Forum honours research professionals each year in order to celebrate Finnish research expertise and to raise awareness and appreciation of clinical drug and device trials....

Breakthroughs in follow-up cancer diagnostics: Recurring cancer can be detected before it reaches full speed

Cancer treatment is becoming more and more personalised. In recent years, the greatest strides in personalised treatment have been made particularly through the development of the genetic and molecular profiling of tumors. The utilisation of information based on genetic diagnostics already offers cancer patients the opportunity to receive targeted treatment and avoid unnecessary treatment and the...

Internal radiotherapy is an effective method of treatment for metastatic prostate cancer – Docrates studied the effectiveness of 177Lu-PSMA treatment with a 4-week treatment interval

Radiopharmaceuticals such as 177Lu-PSMA target prostate cancer cells that express PSMA (prostate-specific membrane antigen), wherever they are, and make cancer treatment possible even if the cancer has spread widely. The 177Lu-PSMA radiopharmaceutical is a type of targeted radiotherapy in which the radiation source is injected directly into or in the immediate vicinity of the cancer cell. It...

A new phenomenon in the field of private cancer treatment: the number of insured patients has more than tripled in five years

Insured patients mean patients who finance their cancer diagnostics and treatment with private insurance under which the insurance compensates some of the patient’s costs. The policyholder and payer may be the patient or their employer. Commercial Director Jani Mikkola believes that the rapid growth in the number of insured patients at Docrates stems from, for example, increased knowledge about...

More and more people are seeking cancer treatment in Finland

Nearly 300 cancer patients from the Nordics underwent treatment at Docrates in 2022. Foreign patients have been treated at Docrates for more than ten years. Docrates has treated almost 2,500 foreign patients from more than 60 countries since 2019. – International patients visiting Docrates seek the latest cancer treatment methods and diagnostics that are not yet available in their home countries....